Q3 2024 Earnings Call Transcript November 12, 2024 Operator: Hello, ladies and gentlemen, and welcome to the Autolus ...
Since 1999, MaxCyte's non-viral cell engineering innovations have helped launch pioneering cell and gene therapy projects. ROCKVILLE, Md., Nov. 13, 2024 (GLOBE NEWSWIRE) -- MaxCyt ...
Acrivon Therapeutics, Inc. ("Acrivon” or "Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage precision medicine company ...
In the world of cell therapy, Silicon Valley has long recognized that technological innovation is the key to solving ...
Should you invest in Bicara Therapeutics Inc? Click for more on BCAX's promising cancer treatment, but proceed with caution ...
Merck KGaA said its cell-tumor treatment Pimicotinib met its primary endpoint ... The drug is being developed by the Chinese biotech Abbisko Therapeutics Co. Merck KGaA holds commercial license for ...
SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the “Company ... The sa-mRNA vaccine candidate is designed to make many copies of mRNA within the host cell after intramuscular ...
Crispr has already secured a historic first approval for a CRISPR/Cas9 drug and has several more potential blockbuster ...
CERo Therapeutics (CERO) announces the presentation of preclinical data demonstrating the capability of its lead compound CER-1236 to kill ...
Data presented as part of a poster at the SITC 2024 ConferenceSOUTH SAN FRANCISCO, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics ...
TipRanks on MSN2d
Syncona’s Autolus Gains FDA Approval for Leukemia TherapySyncona Shs GBP (GB:SYNC) has released an update. Syncona’s portfolio company, Autolus Therapeutics, has received FDA approval for AUCATZYL®, a ...
With Eisai and Biogen’s Leqembi and Eli Lilly’s Kisunla launching onto the market, the 2024 Clinical Trials of Alzheimer’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback